NEWSROOM | Galderma

Galderma prices IPO at CHF 53 per share and will start trading on the SIX Swiss Exchange tomorrow

AMWC 2024: Scientific presentations supported by Galderma

AMWC 2024: Galderma to share new data from its leading injectable aesthetic portfolio

Galderma launches IPO on the SIX Swiss Exchange and sets price range

Dr. Flor A. Mayoral: A story of creativity, passion and dermatological innovation with Galderma

We’re inspired by our people

Galderma @ AAD 2024: new data demonstrate the long-term efficacy of nemolizumab in prurigo nodularis and its durability in atopic dermatitis

Galderma Announces Intention to Float on the SIX Swiss Exchange

Galderma announces record 2023 net sales of over 4 B USD and significant core EBITDA margin expansion

AAD 2024: scientific presentations supported by Galderma

Galderma to showcase latest updates from its broad, innovative and leading dermatology portfolio at the 2024 American Academy of Dermatology annual meeting

Galderma announces regulatory filing acceptance for nemolizumab in prurigo nodularis and atopic dermatitis in the U.S. and EU